KENNESAW, Ga. - CryoLife Inc. reported a third-quarter loss of $19.6 million, including a cost of $27.2 million as the result of a recall of the company's human tissue for reconstructive surgery.<br>
<br>
The results Tuesday provided the first accounting for CryoLife's problems since the Food and Drug Administration ordered the Kennesaw-based company to stop most tissue processing in mid-August.<br>
<br>
CryoLife's shares closed at $4.15, down 18 cents, after the earnings report.<br>
<br>
The FDA said the recall was needed because the company could not be sure its product was free of fungus or bacteria. It followed the death of a Minnesota man from an infection after knee surgery in which CryoLife tissue was used.<br>
<br>
CryoLife executives said they were optimistic that the FDA would agree to reinspect its facility before the end of the year and allow the company to resume all processing.<br>
<br>
